Users online: 2159    [ij] [ij] [ij] 
Email id

Year : 2017, Volume : 10, Issue : 3
First page : ( 369) Last page : ( 376)
Print ISSN : 0974-4169. Online ISSN : 0974-4150.
Article DOI : 10.5958/0974-4150.2017.00063.3

Development of rhenium radiopharmaceuticals from coordination chemistry view point

Sengupta Suman1,*, Panda Bikash Kumar2

1Department of Chemistry, Ananda Chandra College, Jalpaiguri, West Bengal, India. Pin-735101.

2Department of Chemistry, Jangipur College, Jangipur, Murshidabad, West Bengal, India, Pin-742213.

*Corresponding Author E-mail: sengupta.sum@gmail.com

Online published on 22 September, 2017.


Favourable nuclear properties of radiorhenium (188Re and 186Re) are of interest in the development of new radiotherapeutic and molecular imaging agents. A fundamental critical component of a radio-metal based radiopharmaceutical is the chelator, the ligand system that binds the radio metal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. The design of a robust Re conjugate can be achieved through a careful selection of the most stable rhenium cores like [Re≡N]2+ and [Re(CO)3]+ that usually are strongly resistant to hydrolysis by water molecules. The chemistry of rhenium has distinct parallels with its group 7 congener technetium in respect of radiopharmaceutical designing and the resulting species are expected to exhibit similar “in vivo” biological behaviour. The labelling of biologically active molecules to generate affinity of radiorhenium complexes for a specific biological target can be achieved by ‘bifunctional approach’ or by ‘metal fragment’ strategies. This review highlights the role of coordination chemistry in the design of rhenium radiopharmaceuticals engineered to selectively target tissue of interest such as cancer cells. A range of rhenium complexes with different ligands with rhenium in different oxidation states are introduced and their potential to be translated to new radiotherapeutic agents discussed.



Rhenium, Radiopharmaceuticals, Radionuclide therapy, Coordination Chemistry.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
519,084,879 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.